KR20240055101A - 다발성 골수종의 치료 방법 - Google Patents

다발성 골수종의 치료 방법 Download PDF

Info

Publication number
KR20240055101A
KR20240055101A KR1020247011913A KR20247011913A KR20240055101A KR 20240055101 A KR20240055101 A KR 20240055101A KR 1020247011913 A KR1020247011913 A KR 1020247011913A KR 20247011913 A KR20247011913 A KR 20247011913A KR 20240055101 A KR20240055101 A KR 20240055101A
Authority
KR
South Korea
Prior art keywords
antibody
dose
administered
administering
daratumumab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247011913A
Other languages
English (en)
Korean (ko)
Inventor
마이클 스펙터
수잔 비. 소블로프-제인스
Original Assignee
시일럼 바이오사이언시즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시일럼 바이오사이언시즈, 인크. filed Critical 시일럼 바이오사이언시즈, 인크.
Publication of KR20240055101A publication Critical patent/KR20240055101A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/06—Ampoules or carpules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020247011913A 2021-09-14 2022-09-08 다발성 골수종의 치료 방법 Pending KR20240055101A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163244113P 2021-09-14 2021-09-14
US63/244,113 2021-09-14
US202163285435P 2021-12-02 2021-12-02
US63/285,435 2021-12-02
US202263400882P 2022-08-25 2022-08-25
US63/400,882 2022-08-25
PCT/US2022/042944 WO2023043658A2 (en) 2021-09-14 2022-09-08 Method of treating multiple myeloma

Publications (1)

Publication Number Publication Date
KR20240055101A true KR20240055101A (ko) 2024-04-26

Family

ID=85603424

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247011913A Pending KR20240055101A (ko) 2021-09-14 2022-09-08 다발성 골수종의 치료 방법

Country Status (8)

Country Link
US (1) US20240392028A1 (https=)
EP (1) EP4401839A4 (https=)
JP (1) JP2024535132A (https=)
KR (1) KR20240055101A (https=)
AU (1) AU2022346750A1 (https=)
CA (1) CA3231073A1 (https=)
MX (1) MX2024003215A (https=)
WO (1) WO2023043658A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025194030A1 (en) * 2024-03-15 2025-09-18 Alexion Pharmaceuticals, Inc. Treatment of mayo stage iiib light chain amyloidosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5553963B2 (ja) * 2004-10-22 2014-07-23 アムジエン・インコーポレーテツド 組換え抗体をリフォールディングする方法
CR20190291A (es) * 2016-12-23 2019-11-05 Serum Institute Of India Pvt Ltd Métodos mejorados para estimular la productividad de anticuerpos en el cultivo de células de mamiferos y reducir la agregación durante los procesos de formulación post-tratamiento (downstream) y formulaciones de anticuerpos estables obtenidas a partir de los mismos
US20190298827A1 (en) * 2018-04-03 2019-10-03 Janssen Biotech, Inc. Methods of Treating Multiple Myeloma
EP4058479A4 (en) * 2019-11-15 2024-02-28 University of Tennessee Research Foundation MODIFIED IMMUNOLOBULINES FOR TARGETING AMYLOID DEPOSITS
AU2021339851A1 (en) * 2020-09-14 2023-04-13 Caelum Biosciences, Inc. Method of treating amyloidosis

Also Published As

Publication number Publication date
EP4401839A2 (en) 2024-07-24
MX2024003215A (es) 2024-07-19
WO2023043658A3 (en) 2023-05-11
CA3231073A1 (en) 2023-03-23
US20240392028A1 (en) 2024-11-28
AU2022346750A1 (en) 2024-04-11
JP2024535132A (ja) 2024-09-26
EP4401839A4 (en) 2025-08-06
WO2023043658A2 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
KR101320198B1 (ko) 신생물의 치료를 위한 조성물 및 방법
US20260042861A1 (en) Formulations of anti-cd38 antibodies for subcutaneous administration
RU2607022C2 (ru) Способы и композиции для лечения волчанки
US20230340122A1 (en) Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer
US20210196822A1 (en) Treatment of triple negative breast cancer with targeted tgf-b inhibition
US20230364228A1 (en) Method of treating amyloidosis
JP2025537707A (ja) ループス腎炎をＦｃＲｎアンタゴニストを使用して治療するための方法
CN118043072A (zh) 治疗多发性骨髓瘤的方法
US20250074981A1 (en) Combination therapy with dexamethasone and tumor-specific t cell engaging multi-specific antibodies for treating cancer
KR20240055101A (ko) 다발성 골수종의 치료 방법
TW202003577A (zh) 用於在未曾接受過治療之個體治療癌症的標靶性TGF-β抑制之給藥方案
JP2023506779A (ja) 慢性移植片対宿主病の処置用抗体
EA050760B1 (ru) Способ лечения множественной миеломы
CN116782935A (zh) 治疗淀粉样变性的方法
RU2838165C1 (ru) Составы на основе антител к cd38 для подкожного введения
RU2802812C2 (ru) Лечебный подход, предназначенный для лечения комбинацией антитела к CD19 и венетоклакса
JP2025532122A (ja) 黒色腫の治療のための方法及び組成物
TW202606756A (zh) 用於皮下投予之抗cd38抗體的調配物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000